OSP Co., Ltd

OSP Co., Ltd

KKRX:368970
2,080.00
KRW
+45.00
(+2.21%)
-189.50EPS
13.91BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
31,049.12
31,923.73
3,026.54
2,908.77
4,969.88
4,316.24
3,658.3
3,929.86
Basic EPS, GAAP
4,661.33
6,794.66
554.67
190.67
-52
334.67
-474.67
-331.37
Free Cash Flow per Basic Share
1,565.53
5,773.91
-151.46
74.49
-33.81
-687.81
69.31
100.7
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
740.32
1,710.46
2,124.95
4,943.32
4,900.1
5,141.64
4,625.87
4,439.57
Tangible Book Value per Share
713.09
1,674.52
2,089.79
4,908.55
2,139.95
2,515.07
2,074.14
2,101.9
Basic Weighted Avg Shares
- -
- -
5
6
7
7
7
7
Sales/Revenue/Turnover
14,903
15,567
15,695
16,800
35,169
30,309
25,387
27,150
Operating Margin (%)
19.6
25.28
17.86
6.51
5.81
-0.19
-5.03
1.61
Depreciation Expense
416
490
407
509
2,227
2,295
2,453
2,521
Net Income, GAAP
2,237
3,313
2,876
1,101
-368
2,350
-3,294
-2,289
Effective Tax Rate (%)
21.26
18.9
23.12
8.57
- -
7.83
- -
- -
Profit Margin (%)
15.01
21.28
18.33
6.55
-1.05
7.75
-12.98
-8.43
Working Capital
2,095
7,773
9,413
21,895
5,530
5,739
1,443
3,799
LT Debt
61
444
140
189
475
1,875
2,965
1,980
Total Equity
5,189
11,990
14,895
34,651
44,325
48,124
43,582
44,841
Return on Invested Capital (%)
- -
29.29
13.32
3.71
- -
-0.09
- -
- -
Return on Capital (%)
- -
31.78
18.71
4.32
- -
5.07
- -
- -
Return on Common Equity (%)
- -
38.57
21.4
4.45
-1.07
6.68
-9.73
-6.88

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
13,095
14,043
14,175
LT Borrowings
2,783
1,916
1,850
LT Finance Leases
182
154
130
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
17,933
15,987
13,914

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
18,644
18,970
21,086
Cash, Cash Equivalents & STI
10,476
9,527
11,041
Accounts Receivable, Net
3,273
4,545
4,270
Inventories
4,355
4,405
4,606
Total Current Liabilities
17,202
17,887
17,287
Payables & Accruals
- -
- -
- -
ST Debt
13,095
14,043
14,175
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
36.78%
-9.44%
Free Cash Flow
- -
274.08%
-109.96%
Net Income, GAAP
- -
-237.43%
-240.17%
Sales/Revenue/Turnover
- -
17.43%
-16.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,122
7,544
6,104
6,540
30,309
2025
6,421
5,957
6,449
6,561
25,387
2026
7,195
6,945
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
70.67
320
-116
59.84
334.67
2025
-57.33
-160
-97.53
-199.92
-474.67
2026
-66.57
30
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jae-Goo Kang
Full Time Employees
36
Sector
Consumer non-durables
Industry
Food: specialty/candy
Address
Nonsan-si South Korea
IPO Date
Oct 14, 2022
Business
OSP Co., Ltd. is a South Korea-based pet food manufacturing and distribution company primarily engaged in the research, development, production, and commercialization of premium organic animal feed and companion animal nutrition products. Founded in 2004 and headquartered in Nonsan, Chungcheongnam-do, South Korea, the company operates as a subsidiary of animal healthcare enterprise Woogene B&G Co., Ltd. and serves domestic and international pet care markets through original development manufacturing (ODM), original equipment manufacturing (OEM), and proprietary own-brand manufacturing (OBM) business models. The company's core product portfolio encompasses certified organic dry dog food formulated for various life stages, breed sizes, and specialized health needs including weight management, joint mobility, skin and coat health, and sensitive digestion; certified organic dry cat food engineered for urinary tract health, hairball control, gastrointestinal care, and immune support; grain-free, single-protein, and hypoallergenic companion animal diets; semi-moist functional kibbles; and premium nutritional treats and supplements. OSP markets its proprietary pet nutrition offerings under brand names including the Indigo series (encompassing Indigo Natural, Indigo Paw, and Indigo 7) and Natural Lab, while simultaneously producing private-label and contract-manufactured organic pet foods for leading corporate pet food brands. Its manufacturing processes adhere to stringent international quality and safety benchmarks, supported by United States Department of Agriculture National Organic Program (USDA-NOP) certification, South Korean Ministry of Agriculture, Food and Rural Affairs (MAFRA) organic certification, and Hazard Analysis Critical Control Point (HACCP) accreditation. In recent developments, OSP Co., Ltd. completed its initial public offering on the KOSDAQ market of the Korea Exchange under ticker symbol 368970, deploying proceeds toward production automation and brand expansion. To transform its revenue model from an OEM/ODM foundation into a brand-centric global consumer business, the company accelerated the international commercialization of its proprietary Indigo product lineup across Southeast Asian markets, establishing multi-country distribution partnerships in Vietnam, Thailand, the Philippines, Indonesia, and Malaysia, while expanding regulatory registrations in Greater China and the Americas. Domestically, OSP expanded its downstream retail and direct-to-consumer distribution infrastructure through the strategic acquisition of pet specialty distributor Baewha Co., Ltd., bolstering its e-commerce and offline retail channels. Additionally, the company entered the companion animal healthcare technology sector by making strategic equity investments in pet health platform operator Carepet to develop personalized nutrition and preventative healthcare solutions. Operationally, OSP has expanded and modernized capacity at its Nonsan manufacturing complex, integrating smart factory production lines to scale the output of high-margin functional treats and specialized therapeutic pet diets.